Correction to: Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study (International Journal of Hematology, (2022), 116, 2, (215-227), 10.1007/s12185-022-03341-9)

Yoko Edahiro, Kohshi Ohishi, Akihiko Gotoh, Katsuto Takenaka, Hirohiko Shibayama, Takayuki Shimizu, Kensuke Usuki, Kazuya Shimoda, Masafumi Ito, Scott A. VanWart, Oleh Zagrijtschuk, Albert Qin, Hiroaki Kawase, Narihisa Miyachi, Toshiaki Sato, Norio Komatsu, Keita Kirito

研究成果: Comment/debate査読

抄録

In the original publication of the article, in Table 3 [Summary of adverse events (safety population)], the number of patients who developed suicidal ideation related to study drug (n = 1) was erroneously described, and the correct number is 0 (zero). Therefore, the number of patients who developed psychiatric disorders has also been revised from 2 (6.9) to 1 (3.4). The correct Table 3 is given in this correction.

本文言語English
ページ(範囲)642-643
ページ数2
ジャーナルInternational journal of hematology
116
4
DOI
出版ステータスPublished - 2022 10月

ASJC Scopus subject areas

  • 血液学

フィンガープリント

「Correction to: Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study (International Journal of Hematology, (2022), 116, 2, (215-227), 10.1007/s12185-022-03341-9)」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル